URIN D/S- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet Llorens Pharmaceutical International Division

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

URIN D/S

RX ONLY

Urinary antiseptic

NDC 54859-701-10

DESCRIPTION

Each tablet contains:

Methenamine	81.6 mg
Sodium Biphosphate	40.8 mg
Phenyl Salicylate	36.2 mg
Methylene Blue	
Hyoscyamine Sulfate	0.12 mg

Inactive Ingredients: Carbopol 934P, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, dicalcium phosphate, polydextrose, hypromellose, D&C Red #27, titanium dioxide, FD&C Blue #2, triacetin, FD&C Red #40, macrogol, talc.

METHENAMINE. [100-97-0] 1,3,5,7-Tetraazatricyclo [3.3.1.-1 3,7] decane; hexamethylenetetramine; HMT; HMTA; hexamine; 1,3,5,7-tetraazaadamantane hexamethylenemine; Uritone; Urotropin. C6H12N4; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine (hexamethylenetetramine) exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water, soluble in alcohol and in chloroform.

SODIUM BIPHOSPHATE. [7558-80-7] Phosphoric acid sodium salt (1:1); Sodium biphosphate; sodium dihydrogen phosphate; acid sodium phosphate; monosodium orthophosphate; primary sodium phosphate; H2NaO4P; mol wt 119.98, H 1.68%, Na 19.16%, O 53.34%, P 25.82%. Monohydrate, white, odorless slightly deliquesce crystals or granules. At 100° C loses all its water; when ignited it converts to metaphosphate. It is freely soluble in water and practically insoluble in alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous solution at 25° C: 4.5.

PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester; Salol. C13H10O3; mol wt 214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorus oxy-chloride on a mixture of phenol and salicylic acid. Phenyl Salicylate exists as white crystals with a melting point of 41°-43° C. It is very slightly soluble in water and freely soluble in alcohol.

METHYLENE BLUE. [61-73-4] 3,7-Bis(dimethylamino) phenothiazin-5-ium chloride; C.I. Basic Blue 9; methylthioninium chloride; tetramethylthionine chloride; 3,7-bis(dimethylamino) phenazathionium chloride. C16H18ClN3S; mol wt 319.85, C 60.08%, H 5.67%, Cl 11.08%, N 13.14%, S 10.03%. Methylene Blue (Methylthionine chloride) exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.

HYOSCYAMINE SULFATE. [620-61-1][3(S)-endo]-α-(Hydroxymethyl)-benzeneacetic acid 8methyl-8-azabicyclo[3.2.1]oct-3-yl ester sulfate(2:1)(salt); 1αH,5αH-tropan-3α-ol(-)-tropate(ester) sulfate(2:1)(salt);3α-tropanyl S-(-)-tropate; l-tropic acid ester with tropine; l-tropine tropate. C34H48N2O10S. Hyoscyamine Sulfate is an alkaloid of belladonna. Exists as a white crystalline powder. Its solutions are alkaline to litmus. Affected by light, it is slightly soluble in water; freely soluble in alcohol; sparingly soluble in ether.

CLINICAL PHARMACOLOGY

METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70%-90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this at a pH of 5, approximately 20% is formaldehyde. Protein binding - some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.

SODIUM BIPHOSPHATE helps to maintain an acid pH in the urine necessary for the degradation of methenamine.

PHENYL SALICYLATE releases salicylate, a mild analgesic for pain.

METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed by the gastrointestinal tract and rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged.

HYOSCYAMINE SULFATE is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout the body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Its biotransformation is hepatic. Its protein binding is moderate.

INDICATIONS AND USAGE

Indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients is possible.

Risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

WARNINGS

Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs discontinue use immediately.

PRECAUTIONS

Cross sensitivity and/or related problems - patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers.

Pregnancy Category C - Hyoscyamine Sulfate and Methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether UtiraTM-C Tablets cause fetal harm when

administered to a pregnant woman or can affect reproduction capacity. Utira[™]-C Tablets should be given to a pregnant woman only if clearly needed.

Breast-feeding - Problems in humans have not been documented, however, Methenamine and traces of Hyoscyamine Sulfate are excreted in breast milk. Accordingly, Utira[™]-C Tablets should be given to a nursing woman only if clearly needed.

Prolonged Use - there have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.

Pediatric - Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.

Geriatric - Use with caution in elderly patients as they may respond to usual doses of Hyoscyamine Sulfate with excitement, agitation, drowsiness, or confusion.

DRUG INTERACTIONS

Drug Interactions - because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline, reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde). Doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) inhibitors (concurrent use may intensify antimuscarinic side effects), opioid (narcotic analgesics may result in increased risk of severe constipation); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of crystalluria). Patients should be advised that the urine may become blue to blue-green and the feces may be discolored as a result of the excretion of the Methylene blue.

ADVERSE REACTIONS

Cardiovas cular - rapid heartbeat, flushing

Central Nervous System - blurred vision, dizziness, drowsiness

Respiratory - shortness of breath or trouble breathing

Genitourinary - difficult micturition, acute urinary retention

Gastrointestinal - dry mouth, nausea and vomiting

DRUG ABUSE AND DEPENDENCE

A dependence on the use of URIN D/S has not been reported and due to the nature of its ingredients, abuse of URIN D/S is not expected.

OVERDOSAGE

Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5

to 1 mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. Administration of small doses of diazepam to control excitement and seizures. Artificial respiration with oxygen if needed for respiratory depression. Adequate hydration. Symptomatic treatment as necessary.

DOSAGE AND ADMINISTRATION

Adults - one tablet orally 4 times per day followed by liberal fluid intake.

Older Children - Dosage must be individualized by physician. Not recommended for use in children six years of age or younger.

HOW SUPPLIED

URIN D/S is a oval, purple tablet embossed with LLORENS on one side, available in bottles of 100 tablets NDC 54859-701-10 and professional sample bottles of 4 tablets NDC 54859-701-04.

STORAGE

PHARMACIST: Preserve and dispense in tight-light resistant package as defined in the USP.

Store at controlled room temperature between 15-30 degrees C (59-86 degrees F)

Tamper evident by heat seal under cap. Do not use if there is evidence of tampering.

WARNING: Patient should be advised that urine may be colored blue while taking this medication





04/13





URIN D/S BX ONLY

Urinary antiseptic NDC 54859-701-10

Each tablet contains: Methenamine..... Sodium Biphosphate40.8 mg Phenyl Salicylate36.2 mg Hyoscyamine Sulfate 0.12 mg

INACTIVE INGREDIENTS: Carbopol 934P, Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate, Dicalcium Phosphate, Polydextrose, Hypromelliose, DAC Red #27, Titanium Dicaide, FD&C Blue #2, Triacetin, FD&C Red Cellulose, Sodium Hypromellose, D&C R #40, Macrogol, Talc,

Methenamine. [100-97-0] 1.3.5.7-Terkazatógok(3.3.1.1 3.7] decara; heazartelgiovetetarnine; HAT; HATA; heazarine; J.S.Z.Yetekazatowanartan; heazartelgiovetenik; Udion; Uctorgio; CMI1204; red); vi 140;10. C 51.40%; H.8.55%; N.9.59%; Methenamine (heazartelgioveteriamine) decisis as coldense; lastora cystake or white cystalling posteri, jis coldinos are abaitre to Itmus; Freely aduble in water; soluble in elochol and in chloroform.

um Biphosphate, Sodium Biphosphate; sodium Dihydrogen phosphate; acid sodium phosphate; monosodium orthophosphate; primary sodium phosphosphate; [H2NaO4P.] mol wt 119.98. H 1.68%, Na 19.16%, O 53.34%, P 25.82%]. White, odorless, slightly deliquesce crystals or granulies. At 100° loses all its water, when ignited it converts into metaphosphate. It is freely soluble in water and practically insoluble in alpohol. The aq soln is add. PH of 0.1 moder aq soln at 25° 45.

RX ONLY

www.Llorenspharm.com

Phenyl Salicylate. [119-55-8] 24-tyctrocybercolo: acid phenyl ester; Sakd. C19/1003; mol wt 214.22; C 72.89%; H 47/0%; O 22.41%; Made by the action of phosphona. Oxy-attloride on a motume of phonol and salicyle acid; Phenyl Salicylate axists as white crystata with a melting point of 40-43°C. It is very slightly soluble in where and freely oddabi in alcohol.

 Methylane Blue.
 [61-73-4]
 3,7-Bis(dimethylamino) phenothiazin-5-ium chloride;

 C.L. Basic Blue 9; methylthioninum chloride; tetramethylthionine chloride;
 3,7-bis(dimethylamino)
 phenazathionium

 3,7-bis(dimethylamino)
 phenazathionium
 chloride;
 METHYLENE
 BLUE
 nethylthionine chioride) exists as dark green crystals. It is soluble in water and in chloroform: sparingly soluble in alcohol.

Hysosyamine Sulfate, [101-31-6] (3(u)-anci)-a-(Hydroxymethyli benzenesoric acid Benethyl-Beazitoyd2(22,12,045-9) etter; teit/dehropan-Bea/(Hynopa (etter)/a-Beogneth/Subpani, Hydrox acid etter with topic-trajent tropani. Hydroxymeth Sulfate is an elleticid of beliadrma. Exists as a white cystalline product, its acidios en elletino to limax, Meeded by Ight, it is digitly solidale in water, freedy solida spanical spanical spanical spanical spanical spanical solidaria.

CLINICAL PHARMACOLOGY

Methenamine degrades in an actic urine environment releasing formablehyde, which provides bactericial or bacterication action. It is well absorbed from the gastrointestinal fract. 70% to 90% reaches the unive unchanged at which point it is sprodyzed in the unive is actic. Whith 24 hours it is almost completely (80%) ted; of this amount at pH 5, approximately 20% is formaldehyde. Protein binding-some formaldehyde is bound to substances in the urine and surrounding

tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.

Sodium Biphosphate helps to maintain an acid pH in the urine necessary for the degradation of methenamine.

Phenyl Salicylate released salicylate, a mild analossic for pain,

Methylene Blue possesses week anfaeptic properties. It is well absorbed in the gastrointestinal tract and is rapidly reclused to leukomethylene blue which is stabilized in some combination form in the urine, 75% is excreted unchanged.

Hypercyamine Sulfate is a parasympatholytic which releases smooth muscles and thus produces an antisparanoid effect. It is well absorbed from the gastorintershill take and is registeributed throughout body tissues. Most is exervised in the universe within 12 hours, 13% to 55% being unchanged, its biotransformation is hepatic, its matrix buildings. protein binding is

Indexted for the treatment of pryptions of initiative voting, Indicated for the relief of beal symptoms, such as inflammation, hypermotility, and pair, which accompany bear univer yield relations. Indicated for the relief of univery tract symptoms caused by diagnostic procedures.

CONTRAINDICATIONS

Continuendocrational Hypersentifity to any of the ingredients, Risk benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac anythmias, congestive heart failure, coronary heart disease, milrel stenesis); gastreintestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retentio may be precipitated in obstructive uropathy (such as bladder neck obstruction due

to prostatic hypertrophy). The use of MAOIs intended to treat psychiatric disorders with Urin D/S or within 14 days of stopping treatment with Urin D/S is contraindicated because of increased risk for serotonin syndrome. The use of Urin D/S within 14 days of stopping an MAOI intended to treat psychiatric disorders is

WARNINGS Serotonin Syr

Methyden blue is a potent monoamine oxidase inhibitor: Methylene blue has been demonstrated to be a potent monoamine oxidase inhibitor (MACI) and may cause potentially fatal servicini toxicity (serotanin syndrome) when combined with more potential blacks. cause potentially fatal serotonin toxici serotonin reuptake inhibitors (SRIs).

Do not exceed recommended dosage. If rapid pulse, dizziness, or blurring of vision occurs, discontinue use immediately,

PRECAUTIONS

Cross sensitivity and/or related problems - patients intelerant of belladorna alkaloids or sallcylates may be intelerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers.

Pregnancy/Reproduction (FDA Pregnancy Category C) – Hyoscyamine Sulfate and Methenamine cross the placenta, Studies have not been done in animals or humans, It is not known whether URIN D/STM tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. URIN DIS tablets should be given to a pregnant woman only if clearly needed.

ling - problems in humans have not been docume however, Methenamine and traces of Hyoscyamine Sulfate are excreted in breast milk

Prolonged use - there have been no studies to establish the safety of prol use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.

Pediatric - infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.

Geriatric - use with caution in elderly patients as they may respond to usual doses of Hyoscyamine Sulfate with excitement, agitation, drowsiness, or

confusion Drug interactions - because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics medications during concurrent use such as unmary akaitzens; trazisó diuretics (may causa the unice to become akaine reducing the effectiveness of Methemanins by inhibiting its conversion to formabilityob); antimuscurints (concurrent use may internity antimuscarinic effects of Hyposyminis Sultate because of secondrate (may reduce aborption of Hyposyminis Sultate concurrent use with antiacids may cause urine to become abaline exclusion discusse of Mohamma and Markate be become abaline concurrent use winn annaocis may cause urine to become availine reducing effectiveness of Methematine by inhibiting its conversion to formatifivityei) does of these medications should be spaced 1 hour part from doess of Hyposymine Sulfate may further reduce instantial metility; tetoconacele (patients should be adviced to take this combination at beat 2 hours after kenonace); meanmine avical (MAO) inhibites concurrent use with interacting antimucantric side effects, opoid (parcel) and/gesise may result in meanered with charave coercitations, automations, and and there does may interacting antimucantric side effects, opoid (parcel) and/gesise may result in sed risk of severe constication); suffonamides (these drugs may

recipitate with formaldehyde in the urine, increasing the danger of cryst

Patients should be advised that the urine may become blue-to-blue green and the feces may be discolored as a result of the excretion of Methylene blue. Methylene ble may interact with any drug that acts as a seretonin reuptake inhibitor (SRI) induding, amongst others, selective seretonin reuptake inhibitors (SSRIs), sertonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (CrCAs), neergineprine-dopamente reuptake initibilors (NDRIs), triptans and ergot alkabids; such combinations may have the consequence of potentially fatal serotonin toxicity (serotonin syndrome). Methylene blue should not be coadministrated with any drug that acts as an SRL

ADVERSE REACTIONS

AUVENSE HEACTIONS Cardiovascular – znjó dyba, flushing Cantral Nervous System – blured vision, dizziness Respiratory – shortness of breath or toučded breathing Genitourinary – diriculy miculiting, acuto urinary retention GastroIntestinal – dry mouth, nausea/vomiling

DRUG ABUSE AND DEPENDENCE

A dependence on the use of URIN D/S has not been reported and due to the nature of its ingredients, abuse of URIN D/S is not expected.

OVERDOSAGE

Thereis or galatic lawage. Slow intravenous administration of physostigmine in doese of 1 to 4 mg (Ω_5 to 1 mg in children), repeated as needed in one to hwo hours to reverse servere antimuscaninic symptome. Administration of small doese of diazepart to control excitement and seizures. Artificial respiration with oxygent if eeded for respiratory depression. Adequate hydration. Syn necessary,

DOSAGE AND ADMINISTRATION:

Adults - One tablet orally 4 times per day followed by liberal fluid intake. Older children – Dosage must be individualized by physician. Not recommended for use in children up to 6 years of age.

HOW SUPPLIED:

URIN D/S is an oval, purple tablet embossed with LLORENS on one side, available in bottles of 100 tablets NDC 54859-701-10 and professional sample bottles of 4 tablets NDC 54859-701-04.

Tamper evident by heat seal under cap, Do not use if there is evidence of tampering. FOR DOSAGE AND FULL PRESCRIBING INFORMATION, SEE ATTACHED BOOKLET. WARNING: Patient should be advised that

urine may be colored blue while taking this medication.

PHARMACIST: Preserve and dispense in tightlight resistant package as defined in the USP. Store at controlled room temperature between 15-30°C (59-86°F).



URIN D/S

methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet

Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:54859-701			
Route of Administration	ORAL					
Active Ingredient/Active Moiety						

	Ingredient Name		Basis of S	Strength	Strengtl
Methenamine (UNII: J50)OIX95QV) (Methenamine - UNII:J	500IX95QV)	Methenamine		81.6 mg
SODIUM PHOSPHATE, (Sodium Cation - UNII:LY	MO NO BASIC, MO NO HYDRATI /R4M0 NH37)	E (UNII: 593YOG76RN)	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE		40.8 mg
Phenyl Salicylate (UNII	: 28A37T47QO) (Phenyl Salicylate	e - UNII:28A37T47QO)	Phenyl Salicylate		36.2 mg
Methylene Blue (UNII: T UNII:ZMZ79891ZH)	42P99266K) (METHYLENE BLUE	E CATION -	Methylene Blue		10.8 mg
Hyoscyamine Sulfate ((JNII: F2R8 V82B84) (Hyoscyamine	e - UNII:PX44XO846X)	Hyoscyamine Sulfat	e	0.12 mg
Inactive Ingredien	te				
mactive ingreaten		ient Name			Strength
CARBO MER HO MO PO	LYMER TYPE B (ALLYL SUCR		UNII: Z135WT9208)		Strength
MAGNESIUM STEARAT	· · ·	, , , , , , , , , , , , , , , , , , , ,			
	RYSTALLINE (UNII: OP1R32D61	U)			
	COLATE TYPE A CORN (UNII: A	,			
CALCIUM PHO SPHATE	E, DIBASIC, ANHYDROUS (UNII:	L11K75P92J)			
POLYDEXTROSE (UNI	I: VH2XOU12IE)				
HYPROMELLOSES (UN	NII: 3NXW29V3WO)				
D&C RED NO.27 (UNII:	: 2LRS 18 5U6 K)				
TITANIUM DIO XIDE (U	NII: 15FIX9V2JP)				
FD&C BLUE NO. 2 (UN	II: L06K8R7DQK)				
TRIACETIN (UNII: XHX3	3C3X673)				
	JC5/(075)				
FD&C RED NO. 40 (UN	,				
FD&C RED NO.40 (UN	,				
FD&C RED NO.40 (UN	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A)				
FD&C RED NO.40 (UN Polyethylene gly)	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A)				
FD&C RED NO.40 (UN Polyethylene gly)	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U)				
FD&C RED NO. 40 (UN POLYETHYLENE GLY TALC (UNII: 7SEV7J4R1	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U)	Score		no score	
FD&C RED NO. 40 (UN POLYETHYLENE GLYG TALC (UNII: 7SEV7J4R1 Product Character Color	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) *istics purple (purple)			no score 13mm	
FD&C RED NO. 40 (UN POLYETHYLENE GLY TALC (UNII: 7SEV7J4R1 Product Character Color Shape	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U)	Size		13mm	
FD&C RED NO. 40 (UN POLYETHYLENE GLYG TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) *istics purple (purple)				
FD&C RED NO. 40 (UN POLYETHYLENE GLY TALC (UNII: 7SEV7J4R1 Product Character Color Shape	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) *istics purple (purple)	Size		13mm	
FD&C RED NO. 40 (UN POLYETHYLENE GLYG TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) *istics purple (purple)	Size		13mm	
FD&C RED NO. 40 (UN POLYETHYLENE GLYG TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) *istics purple (purple)	Size		13mm	
FD&C RED NO. 40 (UN POLYETHYLENE GLY TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor Contains	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) *istics purple (purple)	Size Imprint Code	Start Date	13mm	d Date
FD&C RED NO. 40 (UN POLYETHYLENE GLYC TALC (UNII: 7SEV7J4R1 Color Shape Flavor Contains Packaging # Item Code	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) rtstcs purple (purple) OVAL (Oval)	Size Imprint Code	Start Date	13mm LLORENS	d Date
FD&C RED NO. 40 (UN POLYETHYLENE GLY TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor Contains Packaging	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) ristics OVAL (purple) OVAL (Oval) OVAL (Oval)	Size Imprint Code	Start Date	13mm LLORENS	d Date
FD&C RED NO. 40 (UN POLYETHYLENE GLYA TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor Contains Packaging # Item Code 1 NDC:54859-701-10	II: WZB9127XOA) COLS (UNII: 3WJQ0SDW1A) U) rtstcs purple (purple) OVAL (Oval) OVAL (Oval) Package Description 100 in 1 BOTTLE	Size Imprint Code	Start Date	13mm LLORENS	d Date
FD&C RED NO. 40 (UN POLYETHYLENE GLYA TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor Contains Packaging # Item Code 1 NDC:54859-701-10	II: ₩ZE9 127XO A) COLS (UNII: 3WJQ0SDW1A) U) ristcs ristcs purple (purple) OVAL (Oval) OVAL (Oval) Package Description 100 in 1 BOTTLE 4 in 1 BOTTLE	Size Imprint Code	Start Date	13mm LLORENS	d Date
FD & C RED NO. 40 (UN POLYETHYLENE GLYA TALC (UNII: 7SEV7J4R1 Product Character Color Shape Flavor Contains # Item Code 1 NDC:54859-701-04	II: ₩ZE9 127XO A) COLS (UNII: 3WJQ0SDW1A) U) ristcs ristcs purple (purple) OVAL (Oval) OVAL (Oval) Package Description 100 in 1 BOTTLE 4 in 1 BOTTLE	Size Imprint Code n Marketing	Start Date	13mm LLORENS Marketing En	

Labeler - Llorens Pharmaceutical International Division (037342305)

Revised: 6/2014